Company Overview of Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company develops exosome-based diagnostics technology platform that harvests comprehensive and dynamic molecular information contained within exosomes from various fresh or frozen biofluids to deliver personalized healthcare to guide treatment decisions and in real-time along the entire patient care continuum. Its technology combines RNA analysis with DNA and protein analysis to deliver comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated, and monitored. The company al...
Riverside Technology Center
840 Memorial Drive
Cambridge, MA 02139
Founded in 2008
Key Executives for Exosome Diagnostics, Inc.
Chief Executive Officer and Director
Chief Science Officer and Founding Scientist
Vice President of Business Development
Compensation as of Fiscal Year 2014.
Exosome Diagnostics, Inc. Key Developments
Exosome Diagnostics, Inc. Announces Positive Results from Initial Clinical Study of Novel Prostate Cancer Liquid Biopsy
Feb 26 15
Exosome Diagnostics, Inc. announced positive data from an initial clinical study of the company's novel prostate cancer liquid biopsy. The non-invasive, RNA-based test demonstrated the potential to accurately predict high-grade prostate cancer by analyzing biomarkers on exosomal RNA (exoRNA) via a simple urine sample. The data were presented at a poster session titled, A first catch, non-DRE urine exosome gene signature to predict Gleason 7 prostate cancer on an initial prostate biopsy, at the 2015 Genitourinary Cancers Symposium taking place February 26-28, 2015 in Orlando, Florida.
Exosome Diagnostics, Inc. and Addario Lung Cancer Medical Institute Announce Collaboration to Accelerate Development of Plasma-Based Lung Cancer Diagnostics
Jan 9 15
Exosome Diagnostics, Inc. announced a strategic collaboration with the Addario Lung Cancer Medical Institute (ALCMI) to accelerate the development of its lead plasma-based diagnostics in development for mutation detection and monitoring in patients with lung cancer. The collaboration will support validation of Exosome Diagnostics ALK and T790M lab developed tests (LDTs) planned to launch in 2015 and help advance future development of the company’s ALK and T790M in vitro diagnostic (IVD) kits. Exosome Diagnostics ALK and T790M tests have the potential to provide clinicians with real-time, precise molecular insights to help inform individualized treatment decisions for patients with lung cancer upon initial diagnosis and throughout the course of treatment. Exosome Diagnostics novel technology platform enables the development of tests that can analyze stable, high-quality exosomal RNA (exoRNA), representing a potentially important advance given that many known cancer mutations, such as gene arrangements and splice variants, are difficult or impossible to detect utilizing circulating DNA analysis.
Exosome Diagnostics Appoints Thomas McLain as Chief Executive Officer, Effective July 23, 2014
Aug 4 14
Exosome Diagnostics announced the appointment of Thomas McLain as its chief executive officer, effective July 23, 2014. Mr. McLain most recently was the CEO of Vermillion.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|